Filing Flows › Mirum Pharmaceuticals (MIRM) › Bile Acid Medicines revenue
Mirum Pharmaceuticals (MIRM) Bile Acid Medicines revenue by quarter
Mirum Pharmaceuticals' Bile Acid Medicines revenue was $52.3M in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 7 quarters it ranged from $38.4M (Q1 2025) to $52.3M (Q3 2026).
| Quarter | Bile Acid Medicines revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $52.3M | +10% | +28% |
| Q2 2026 | $47.5M | +3% | +20% |
| Q1 2026 | $46.1M | +8% | +20% |
| Q4 2025 | $42.5M | +4% | — |
| Q3 2025 | $40.8M | +3% | — |
| Q2 2025 | $39.6M | +3% | — |
| Q1 2025 | $38.4M | — | — |
Q3 2026 at a glance
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Mirum Pharmaceuticals' Bile Acid Medicines revenue?
Mirum Pharmaceuticals' Bile Acid Medicines revenue was $52.3M in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has Mirum Pharmaceuticals' Bile Acid Medicines revenue changed?
Over the last 7 quarters it ranged from $38.4M (Q1 2025) to $52.3M (Q3 2026).